MX2020008767A - Disruptores del dímero egfr y uso de estos. - Google Patents

Disruptores del dímero egfr y uso de estos.

Info

Publication number
MX2020008767A
MX2020008767A MX2020008767A MX2020008767A MX2020008767A MX 2020008767 A MX2020008767 A MX 2020008767A MX 2020008767 A MX2020008767 A MX 2020008767A MX 2020008767 A MX2020008767 A MX 2020008767A MX 2020008767 A MX2020008767 A MX 2020008767A
Authority
MX
Mexico
Prior art keywords
same
disruptors
egfr dimer
egfr
dimer
Prior art date
Application number
MX2020008767A
Other languages
English (en)
Spanish (es)
Inventor
Mukesh K Nyati
Theodore S Lawrence
Christopher Whitehead
Jason Christopher Rech
Brennan Taylor Watch
Original Assignee
Univ Michigan Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan Regents filed Critical Univ Michigan Regents
Publication of MX2020008767A publication Critical patent/MX2020008767A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2020008767A 2018-02-23 2019-02-25 Disruptores del dímero egfr y uso de estos. MX2020008767A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862634452P 2018-02-23 2018-02-23
PCT/US2019/019391 WO2019165358A1 (en) 2018-02-23 2019-02-25 Egfr dimer disruptors and use of the same

Publications (1)

Publication Number Publication Date
MX2020008767A true MX2020008767A (es) 2021-01-08

Family

ID=67688515

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008767A MX2020008767A (es) 2018-02-23 2019-02-25 Disruptores del dímero egfr y uso de estos.

Country Status (11)

Country Link
US (2) US11358965B2 (cg-RX-API-DMAC7.html)
EP (1) EP3755323A4 (cg-RX-API-DMAC7.html)
JP (2) JP7497046B2 (cg-RX-API-DMAC7.html)
KR (1) KR102748047B1 (cg-RX-API-DMAC7.html)
CN (1) CN111886009A (cg-RX-API-DMAC7.html)
AU (1) AU2019223168B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020017184A2 (cg-RX-API-DMAC7.html)
CA (1) CA3091834A1 (cg-RX-API-DMAC7.html)
EA (1) EA202092000A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020008767A (cg-RX-API-DMAC7.html)
WO (1) WO2019165358A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019223168B2 (en) 2018-02-23 2024-09-12 The Regents Of The University Of Michigan EGFR dimer disruptors and use of the same
CN119454706A (zh) * 2019-08-22 2025-02-18 密歇根大学董事会 治疗kras相关癌症的方法
IL296091A (en) * 2020-03-05 2022-11-01 Univ Michigan Regents Inhibitors of braf, kras, egfr and other targets and their uses
CN115397413A (zh) * 2020-03-05 2022-11-25 密歇根大学董事会 Egfr、kras、braf和其他靶标的抑制剂及其用途
MX2023003362A (es) 2020-09-23 2023-05-30 Scorpion Therapeutics Inc Derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer.
WO2022072645A2 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Methods for treating cancer
TW202229282A (zh) 2020-09-30 2022-08-01 美商史考皮恩治療有限公司 治療癌症之方法
WO2022072632A1 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Bicyclic compounds for use in the treatment cancer
BR112023006531A2 (pt) 2020-10-09 2023-10-03 Scorpion Therapeutics Inc Inibidores heterocílicos de egfr e/ou her2, para uso no tratamento de câncer
WO2022077154A1 (en) * 2020-10-12 2022-04-21 The Regents Of The University Of Michigan Synthesis of egfr modulators
CN116997551A (zh) * 2020-10-12 2023-11-03 密歇根大学董事会 Egfr调节剂的合成
WO2022094271A1 (en) 2020-10-30 2022-05-05 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022098992A1 (en) 2020-11-05 2022-05-12 Scorpion Therapeutics, Inc. Use of macrocyclic compounds in methods of treating cancer
WO2022197913A1 (en) 2021-03-18 2022-09-22 Scorpion Therapeutics, Inc. Bicyclic derivatives which can be used to treat cancer
KR20240016250A (ko) * 2021-04-02 2024-02-06 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료를 위한 병용요법
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
WO2023173083A1 (en) 2022-03-11 2023-09-14 Scorpion Therapeutics, Inc. Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer
WO2024254298A1 (en) 2023-06-08 2024-12-12 Scorpion Therapeutics, Inc. A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer
EP4724150A1 (en) 2023-06-08 2026-04-15 Antares Therapeutics, Inc. A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3547977A (en) 1967-10-27 1970-12-15 Velsicol Chemical Corp Novel carbanilates
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US9029502B2 (en) 2010-12-20 2015-05-12 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
WO2014176475A2 (en) * 2013-04-26 2014-10-30 The Regents Of The University Of Michigan Egfr inhibitors and uses thereof
EP3096761A1 (en) * 2014-01-24 2016-11-30 Confluence Life Sciences, Inc. Substituted pyroolopyridines and pyrrolopyrazines for treating cancer or inflammatory diseases
WO2016105525A2 (en) * 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Novel pyrimidines as egfr inhibitors and methods of treating disorders
AU2019223168B2 (en) * 2018-02-23 2024-09-12 The Regents Of The University Of Michigan EGFR dimer disruptors and use of the same

Also Published As

Publication number Publication date
BR112020017184A2 (pt) 2020-12-22
EP3755323A4 (en) 2021-11-24
US11999731B2 (en) 2024-06-04
KR102748047B1 (ko) 2024-12-27
AU2019223168A1 (en) 2020-09-10
EA202092000A1 (ru) 2020-12-09
CN111886009A (zh) 2020-11-03
AU2019223168B2 (en) 2024-09-12
EP3755323A1 (en) 2020-12-30
WO2019165358A1 (en) 2019-08-29
CA3091834A1 (en) 2019-08-29
US20220340572A1 (en) 2022-10-27
KR20200124709A (ko) 2020-11-03
US20200377503A1 (en) 2020-12-03
JP2024056735A (ja) 2024-04-23
JP2021514001A (ja) 2021-06-03
JP7497046B2 (ja) 2024-06-10
US11358965B2 (en) 2022-06-14

Similar Documents

Publication Publication Date Title
EA202092000A1 (ru) Ингибиторы димеризации egfr и их использование
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
EA201992497A1 (ru) МОДУЛЯТОРЫ K-Ras
MX392368B (es) Composiciones y metodos para el tratamiento del cancer
ZA201906111B (en) Cyclic di-nucleotides compounds for the treatment of cancer
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
PH12022550646A1 (en) Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
PH12020500371A1 (en) Spirocycle compounds and methods of making and using same
ZA202102202B (en) Androgen receptor modulators and methods for their use
EA201792443A1 (ru) МОДУЛЯТОРЫ K-Ras
TW201613647A (en) Compounds and compositions for treating HER2 positive tumors
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
EA201790921A1 (ru) Замещенные производные 2-анилинпиримидина в качестве модуляторов egfr
PH12016502607A1 (en) Functionalised and substituted indoles as anti-cancer agents
MX2017010595A (es) Métodos, composiciones, y equipos para tratamiento de cáncer.
MX2020006297A (es) Variantes de cd19.
AU2016246521A8 (en) Treatment of lung cancer with inhibitors of glutaminase
JOP20200023A1 (ar) مركبات حلقية لولبية وطرق تصنيعها واستخدامها
MX2024012294A (es) RECEPTORES DE TGF-ß Y MÉTODOS DE USO
PH12020551543A1 (en) Therapeutic modulators of the reverse mode of atp synthase
EP4286005A3 (en) Cancer treatment
WO2019182867A8 (en) Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
MX2020012990A (es) Formulaciones de tegavivint y compuestos relacionados.